TRENDS IN VOLUMES OF ADULT AND PAEDIATRIC ARV FORMULATIONS ... · 1 | 08 march 2016 trends in...
Transcript of TRENDS IN VOLUMES OF ADULT AND PAEDIATRIC ARV FORMULATIONS ... · 1 | 08 march 2016 trends in...
08 March 2016 1 |
TRENDS IN VOLUMES OF ADULT AND PAEDIATRIC
ARV FORMULATIONS IN LMICS.
PRELIMINARY ANALYSIS FROM THE GPRM DATA
Boniface Dongmo-Nguimfack
WHO/HIV/SIP
08 March 2016 2 |
Denominator used for calculation: Years and number of patient-years
Years 2011 2012 2013 2014 2015
Thousands API Years 16,970 22,391 28,761 29,287 27,074
Thousands Patient Years 5,657 7,464 9,587 9,762 9,025
08 March 2016 3 |
Data included
CHAI/UNITAID:
– Data included up to 09.2014
GFATM
– PQR data included up to 31. 12.2015 – but 2015 not complete given reporting delays in PQR
SCMS
– Data included up to 31.12.2015
Rest of PEPFAR
– Data included up to 12.2013
UNICEF
– Data included up to 31.12.2015
IDA:
– Data included up to 31.12.2015
MISSIONPHARMA
– Data included up to 04.2015
WHOCPS
– Data included up to 31.12.2015
08 March 2016 4 |
Market share (% of total volume in PYR of nucleoside reverse transcriptase inhibitors, excluding FTC and 3TC)
08 March 2016 5 |
Market share (% of total volume in PYR of 3TC and FTC)
08 March 2016 6 |
Market share (% of total volume in PYR of EFV, NVP and ETV)
08 March 2016 7 |
Market share (% of total volume in PYR of protease inhibitors, excluding ritonavir)
08 March 2016 8 |
Relative uptake of tenofovir containing
formulations
08 March 2016 9 |
Relative uptake of zidovudine containing formulations
08 March 2016 10 |
FORECASTING DEMAND FOR ARVS
-
TRENDS OF PEDIATRIC FORMULATIONS UPTAKE
FROM THE GPRM DATABASE
08 March 2016 11 |
Denominator used for calculation: Years and Number of Patient Years
2011 2012 2013 2014 2015
Thousands API Years 1,119 981 1,513 1,329 552
Thousands Patient Years 373 327 504 443 184
08 March 2016 12 |
Market share (%) of nucleoside reverse transcriptase inhibitors (excluding 3TC and FTC)
08 March 2016 13 |
Relative uptake of abacavir containing formulations
08 March 2016 14 |
Relative uptake of didanosine formulations
08 March 2016 15 |
Relative uptake of different zidovudine containing formulations
08 March 2016 16 |
Relative uptake of stavudine containing formulations
08 March 2016 17 |
Relative uptake of different lopinavir formulations
08 March 2016 18 |
Relative market share of non-nucleoside reverse transcriptase inhibitors plus LPV
08 March 2016 19 |
Thank you